Show simple item record

dc.contributor.authorLord, Philip
dc.contributor.authorSpiering, Rachel
dc.contributor.authorAguillon, Juan C.
dc.contributor.authorAnderson, Amy E.
dc.contributor.authorAppel, Silke
dc.contributor.authorBenitez-Ribas, Daniel
dc.contributor.authorten Brinke, Anja
dc.contributor.authorBroere, Femke
dc.contributor.authorCools, Nathalie
dc.contributor.authorCuturi, María Cristina
dc.contributor.authorDiboll, Julie
dc.contributor.authorGeissler, Edward
dc.contributor.authorGiannoukakis, Nick
dc.contributor.authorGregori, Silvia
dc.contributor.authorvan Ham, Sija Marieke
dc.contributor.authorLattimer, Staci
dc.contributor.authorMarshall, Lindsay F.
dc.contributor.authorHarry, Rachel A.
dc.contributor.authorHutchinson, James A.
dc.contributor.authorIsaacs, John D.
dc.contributor.authorJoosten, Irma
dc.contributor.authorvan Kooten, Cees
dc.contributor.authorde Cerio, Ascensión López Díaz
dc.contributor.authorNikolic, Tatjana
dc.contributor.authorOral, Haluk Barbaros
dc.contributor.authorSofronic-Milosavljevic, Ljiljana
dc.contributor.authorRitter, Thomas
dc.contributor.authorRiquelme, Paloma
dc.contributor.authorThomson, Angus W.
dc.contributor.authorTrucco, Massimo
dc.contributor.authorVives-Pi, Marta
dc.contributor.authorMartinez-Caceres, Eva M.
dc.contributor.authorHilkens, Catharien M.U.
dc.identifier.citationLord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, ten Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N, Gregori S, van Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs JD, Joosten I, van Kooten C, Lopez Diaz de Cerio A, Nikolic T, Oral HB, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M, Martinez-Caceres EM, Hilkens CMU. (2016) Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ 4:e2300
dc.description.abstractCellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.en_IE
dc.description.sponsorshipThis work was supported by a grant from the European Cooperation in Science and Technology (COST) for the AFACTT project (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies; BM1305). COST is part of the EU Framework Programme Horizon 2020.en_IE
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.subjectCell therapyen_IE
dc.subjectMinimum information modelen_IE
dc.subjectAntigen-presenting cellsen_IE
dc.subjectAutoimmune diseaseen_IE
dc.subjectTolerogenic dendritic cellsen_IE
dc.subjectRegulatory macrophagesen_IE
dc.subjectReporting guidelinesen_IE
dc.subjectDendritic cellsen_IE
dc.titleMinimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapiesen_IE
dc.local.contactThomas Ritter, School Of Medicine, Regenerative Medicine Institute, Biosciences, Dangan. 5329 Email:

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland